Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study
Standard
Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. / Mühlemann, Barbara; Thibeault, Charlotte; Hillus, David; Helbig, Elisa T; Lippert, Lena J; Tober-Lau, Pinkus; Schwarz, Tatjana; Müller, Marcel A; Witzenrath, Martin; Suttorp, Norbert; Sander, Leif E; Drosten, Christian; Jones, Terry C; Corman, Victor M; Kurth, Florian; Pa-COVID Study Group.
in: CLIN MICROBIOL INFEC, Jahrgang 27, Nr. 10, 2021, S. 1520.e7-1520.e10.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study
AU - Mühlemann, Barbara
AU - Thibeault, Charlotte
AU - Hillus, David
AU - Helbig, Elisa T
AU - Lippert, Lena J
AU - Tober-Lau, Pinkus
AU - Schwarz, Tatjana
AU - Müller, Marcel A
AU - Witzenrath, Martin
AU - Suttorp, Norbert
AU - Sander, Leif E
AU - Drosten, Christian
AU - Jones, Terry C
AU - Corman, Victor M
AU - Kurth, Florian
AU - Pa-COVID Study Group
N1 - Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
PY - 2021
Y1 - 2021
N2 - OBJECTIVES: Dexamethasone has become the standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives of this work were to characterize the kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentration in the upper respiratory tract (URT) and the antibody response in patients with (D+) and without (D-) dexamethasone treatment.METHODS: Data and biosamples from hospitalized patients with severe COVID-19, enrolled between 4th March and 11th December 2020 in a prospective observational study, were analysed. SARS-CoV-2 virus concentration in serial URT samples was measured using RT-PCR. SARS-CoV-2-specific immunoglobulins A and G (IgA and IgG) were measured in serum samples using S1-ELISA.RESULTS: We compared 101 immunocompetent patients who received dexamethasone (according to the inclusion criteria and dosage determined in the RECOVERY trial) to 93 immunocompetent patients with comparable disease severity from the first months of the pandemic, who had not been treated with dexamethasone or other glucocorticoids. We found no inter-group differences in virus concentration kinetics, duration of presence of viral loads >106 viral copies/mL (D+ median 17 days (IQR 13-24), D- 19 days (IQR 13-29)), or time from symptom onset until seroconversion (IgA: D+ median 11.5 days (IQR 11-12), D- 14 days (IQR 11.5-15.75); IgG: D+ 13 days (IQR 12-14.5), D- 12 days (IQR 11-15)).CONCLUSION: Dexamethasone does not appear to lead to a change in virus clearance or a delay in antibody response in immunocompetent patients hospitalized with severe COVID-19.
AB - OBJECTIVES: Dexamethasone has become the standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives of this work were to characterize the kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentration in the upper respiratory tract (URT) and the antibody response in patients with (D+) and without (D-) dexamethasone treatment.METHODS: Data and biosamples from hospitalized patients with severe COVID-19, enrolled between 4th March and 11th December 2020 in a prospective observational study, were analysed. SARS-CoV-2 virus concentration in serial URT samples was measured using RT-PCR. SARS-CoV-2-specific immunoglobulins A and G (IgA and IgG) were measured in serum samples using S1-ELISA.RESULTS: We compared 101 immunocompetent patients who received dexamethasone (according to the inclusion criteria and dosage determined in the RECOVERY trial) to 93 immunocompetent patients with comparable disease severity from the first months of the pandemic, who had not been treated with dexamethasone or other glucocorticoids. We found no inter-group differences in virus concentration kinetics, duration of presence of viral loads >106 viral copies/mL (D+ median 17 days (IQR 13-24), D- 19 days (IQR 13-29)), or time from symptom onset until seroconversion (IgA: D+ median 11.5 days (IQR 11-12), D- 14 days (IQR 11.5-15.75); IgG: D+ 13 days (IQR 12-14.5), D- 12 days (IQR 11-15)).CONCLUSION: Dexamethasone does not appear to lead to a change in virus clearance or a delay in antibody response in immunocompetent patients hospitalized with severe COVID-19.
KW - Anti-Inflammatory Agents/therapeutic use
KW - Antibodies, Viral/blood
KW - COVID-19/blood
KW - Dexamethasone/therapeutic use
KW - Hospitalization
KW - Humans
KW - Immunoglobulin A/blood
KW - Immunoglobulin G/blood
KW - Kinetics
KW - Prospective Studies
KW - RNA, Viral/analysis
KW - Respiratory System/virology
KW - SARS-CoV-2/genetics
KW - Seroconversion
KW - Viral Load
U2 - 10.1016/j.cmi.2021.06.008
DO - 10.1016/j.cmi.2021.06.008
M3 - SCORING: Journal article
C2 - 34139335
VL - 27
SP - 1520.e7-1520.e10
JO - CLIN MICROBIOL INFEC
JF - CLIN MICROBIOL INFEC
SN - 1198-743X
IS - 10
ER -
